Temasek, cor­po­rate VCs buy in­to pre­scrip­tion dig­i­tal med hopes in Ak­il­i's $55M Se­ries C

Just how hot is “pre­scrip­tion dig­i­tal med­i­cine” these days? Ask the in­vestors back­ing Ak­ili In­ter­ac­tive, who col­lec­tive­ly sank $55 mil­lion in a Se­ries C an­nounced this morn­ing.

Boston-based Ak­ili, a PureTech af­fil­i­ate, is de­vel­op­ing a late-stage video game for pe­di­atric at­ten­tion deficit/hy­per­ac­tiv­i­ty dis­or­der (AD­HD) along­side oth­er soft­ware pro­grams in autism, de­pres­sion and mul­ti­ple scle­ro­sis. Temasek led the lat­est round, with par­tic­i­pa­tion from cor­po­rate VCs like Am­gen Ven­tures and M Ven­tures (of Mer­ck KGaA) as well as Jazz Ven­ture Part­ners, Bail­lie Gif­ford and Canepa Ad­vanced Health­care Fund — a group that co-founder and CEO Ed­die Mar­tuc­ci de­scribes as bring­ing “suc­cess­ful long-term track records in in­no­v­a­tive tech­nol­o­gy, med­ical de­vice and phar­ma­ceu­ti­cal in­vest­ment.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER